New HIV injection not advised for pregnant women, says FG
The Federal Government has clarified that the new long-acting HIV prevention injection, Lenacapavir (LenPrEP), should not be used by pregnant women. Temitope Ilori, Director-General of the National Agency for the Control of AIDS, explained the restriction is due to insufficient evidence about its effects during pregnancy. Adebobola Bashorun from the National AIDS and STDs Control Programme said efforts are ongoing to expand access to the drug for those most at risk. Public health experts have welcomed Lenacapavir as a promising addition to HIV prevention, but stress the need for equitable access and sustainable funding.
Highlights
- Temitope Ilori stated that Lenacapavir is not recommended for pregnant women, despite its high safety margin in global studies.
- The injection is a preventive measure, not a treatment, and does not protect against other sexually transmitted infections or hepatitis.
- Adebobola Bashorun noted that side effects have mostly been mild and limited to injection-site reactions.
- The Federal Government, with support from the Global Fund, is working to expand access and explore local production for long-term sustainability.
- Experts emphasize that while Lenacapavir is a breakthrough, its success depends on integration into existing programmes, sustained funding, and continued focus on other health priorities.
